Average Sales Price Final Rule Includes PhRMA’s Estimation Method
Executive Summary
The methodology for estimating drug price concessions when submitting average sales prices for Medicare Part B will follow a proposal made by drug manufacturers in comments to the interim final rule
You may also be interested in...
Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says
Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said
Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says
Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said
Average Sales Price Creates Inflationary Pressure, Former CMS Head Says
The use of average sales price for reimbursement of Medicare Part B-covered drugs puts inflationary pressure on drug prices, former Centers for Medicare & Medicaid Services Administrator Thomas Scully said